Advertisement · 728 × 90

Posts by Odysseas Vavourakis

Post image

New OpenFold3 preview out! (OF3p2)

It closes the gap to AlphaFold3 for most modalities.

Most critically, we're releasing everything, including training sets & configs, making OF3p2 the only current AF3-based model that is functionally trainable & reproducible from scratch🧵1/9

1 month ago 245 91 1 2
Preview
Frontiers | Time in mind: a multidisciplinary review on temporal perception, cognition, and memory This review examines temporal cognition through the lens of Mental Time Travel (MTT): the subjective experience of recalling past events and using them to co...

I’m excited to share my first peer-reviewed publication, and my first first-author paper, "Time in mind: a multidisciplinary review on temporal perception, cognition, and memory" is now published open access in Frontiers in Cognition!
www.frontiersin.org/journals/cog... #psychology #science #time

2 months ago 4 1 1 0

Thank you for pointing this out. This was due to hitch in our update pipeline; ANARCI seems to number the sequence fine. This entry has now been corrected.

6 months ago 1 0 0 0

Predicting protein conformational flexibility remains a major challenge in structural biology. While we can now accurately model static protein structures, understanding their dynamics is still difficult, largely due to a lack of suitable training data.

1 year ago 5 1 1 1

Huge thanks 🙌 to my fellow members of @opig.stats.ox.ac.uk:

- our lead author Alex Greenshields-Watson
- my co-authors Fabian Spoendlin and @mcagiada.bsky.social
- and our extraordinary P.I. Charlotte Deane!

Have questions or thoughts? Let’s discuss! 🧬

1 year ago 1 0 0 0
Preview
Challenges and compromises: Predicting unbound antibody structures with deep learning Therapeutic antibodies are manufactured, stored and administered in the free state; this makes understanding the unbound form key to designing and imp…

The future of antibody design is bright, and we’re excited to contribute to it! 🌟

Check out the paper for full details!

1 year ago 1 0 1 0

They also give rise to probabilistic metrics (e.g. conformational likelihoods) that could better reflect state occupancies and outperform current metrics as ranking and filtering criteria.

Plus, generative models open the door to robust, antigen-conditional de novo design. 🚀

7/

1 year ago 0 0 1 0

We also suggest generative approaches (like diffusion or flow matching) can help!

Here’s why:
• They target conformational distributions directly as the learning objective.
• They sample these distributions efficiently.

6/

1 year ago 0 0 1 0

We call for:
🧠 More ML-grade unbound data for training predictors,
✅ Better methods to rank/QC structure predictions + estimate uncertainty,
🔄 Improved flexibility/ensemble predictions,
🔬 Carrying multiple conformations into downstream analyses.

5/

1 year ago 0 0 1 0

In other words, designing better-targeted, more reliable antibodies demands better handling of multiple conformations!

Our paper highlights these challenges, reviews current antibody structure predictors (e.g. AF3, ESM3, ABodyBuilder3), and proposes key directions for progress.

4/

1 year ago 0 0 1 0
Advertisement

Worse, this conformational heterogeneity directly affects antibody function!
• Entropic contributions influence binding and affinity (ΔG=ΔH–TΔS).
• Flexibility impacts many therapeutic traits.
• Flexibility could even be exploited—e.g., pH-sensitive antibodies that “switch on” inside tumours! 🧪

3/

1 year ago 0 0 1 0

Therapeutic antibodies are manufactured, stored, and administered in their free (unbound) state.

So predicting that conformation is crucial! It’s also hard:
1️⃣ Most antibody structures in the PDB are bound forms, leaving little unbound data.
2️⃣ CDR loops are flexible—literal moving targets!

2/

1 year ago 0 0 1 0
Preview
Challenges and compromises: Predicting unbound antibody structures with deep learning Therapeutic antibodies are manufactured, stored and administered in the free state; this makes understanding the unbound form key to designing and imp…

It’s an exciting time in protein design! 🧬✨ But much of the therapeutic potential—especially for antibodies—remains untapped. Why? 🤔

Antibodies seem like ideal candidates for design! 💉
Here’s a quick thread summarising our new review paper on the state of antibody structure prediction. 👇

1/

1 year ago 7 1 1 1